FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2679423891> ?p ?o ?g. }

• W2679423891 endingPage "3014" @default.
• W2679423891 startingPage "3014" @default.
• W2679423891 abstract "3014 Background: The inhibitory PD-L1 and CTLA-4 pathways control T-cell activation. MEDI4736 (M) is a human IgG1 mAb that blocks PD-L1 binding to programmed cell death-1 and CD80 with high affinity and selectivity. Tremelimumab (T) is a selective human IgG2 mAb inhibitor of CTLA-4. M and T have demonstrated acceptable safety profiles and clinical activity as single agents. M and T block distinct interactions contributing to immunosuppression and the combination may provide greater antitumor activity versus either agent alone. Methods: A Phase 1, open-label dose escalation and expansion study (NCT02000947) is assessing the safety/tolerability and antitumor activity of M + T combinations in pts with advanced NSCLC. Results: As of 4 Dec 2014, 61 pts have been treated during the dose escalation phase (table). An MTD has not yet been defined; the Cohort 5a dose exceeded the MTD (n=2 with dose-limiting toxicities; Grade [G] 3 increased AST/ALT, G4 increased lipase). 64% of pts had ≥1 drug-related AE; the most frequent were fatigue (26%), diarrhea (21%), and increased amylase (13%). 31% of pts had ≥1 G3/4 related AE; the most frequent (>5%) were diarrhea (8%) and colitis (7%). Increasing doses of T with a constant dose of M were associated with greater severity and frequency of AEs. 18% of pts had drug-related AEs leading to discontinuation; the most frequent was colitis (7%). All AEs were manageable with standard therapy, including steroids, except G4 myasthenia gravis and G5 polymyositis in 1 pt in Cohort 2a. Of 31 pts with ≥18-week scan, 8 (26%) had partial response (PR) and 11 pts (35%) had stable disease. PRs occurred in 3 of 10 pts with PD-L1-negative tumors. Conclusions: The combination has a manageable safety profile with evidence of clinical activity, including in PD-L1-negative disease. These data support continued study of the combination; recruitment is ongoing. Clinical trial information: NCT02000947. M Q4W M Q2W Cohort 1a 2a 3a 3b 4 4a 5 5a 8 9 Dose M (mg/kg) + T (mg/kg) 3 + 1 10 + 1 15 + 1 10 + 3 20 + 1 15 + 3 15 + 10 20 + 3 10 + 1 10 + 3 n 3 3 11 3 6 11 9 6 3 6 Pts with ≥1 drug- related AE, n All grades 1 3 5 3 2 7 8 5 0 5 Grade 3/4 0 2 2 1 1 2 4 5 0 2 All grades leading to discontinuation 0 1 1 1 0 2 2 3 0 1" @default.
• W2679423891 created "2017-06-30" @default.
• W2679423891 creator A5005462156 @default.
• W2679423891 creator A5028192791 @default.
• W2679423891 creator A5040663360 @default.
• W2679423891 creator A5046273815 @default.
• W2679423891 creator A5052730435 @default.
• W2679423891 creator A5062235853 @default.
• W2679423891 creator A5069189562 @default.
• W2679423891 creator A5075877134 @default.
• W2679423891 creator A5076873642 @default.
• W2679423891 creator A5087435355 @default.
• W2679423891 date "2015-05-20" @default.
• W2679423891 modified "2023-10-03" @default.
• W2679423891 title "Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC." @default.
• W2679423891 doi "https://doi.org/10.1200/jco.2015.33.15_suppl.3014" @default.
• W2679423891 hasPublicationYear "2015" @default.
• W2679423891 type Work @default.
• W2679423891 sameAs 2679423891 @default.
• W2679423891 citedByCount "26" @default.
• W2679423891 countsByYear W26794238912015 @default.
• W2679423891 countsByYear W26794238912016 @default.
• W2679423891 countsByYear W26794238912017 @default.
• W2679423891 countsByYear W26794238912019 @default.
• W2679423891 countsByYear W26794238912020 @default.
• W2679423891 crossrefType "journal-article" @default.
• W2679423891 hasAuthorship W2679423891A5005462156 @default.
• W2679423891 hasAuthorship W2679423891A5028192791 @default.
• W2679423891 hasAuthorship W2679423891A5040663360 @default.
• W2679423891 hasAuthorship W2679423891A5046273815 @default.
• W2679423891 hasAuthorship W2679423891A5052730435 @default.
• W2679423891 hasAuthorship W2679423891A5062235853 @default.
• W2679423891 hasAuthorship W2679423891A5069189562 @default.
• W2679423891 hasAuthorship W2679423891A5075877134 @default.
• W2679423891 hasAuthorship W2679423891A5076873642 @default.
• W2679423891 hasAuthorship W2679423891A5087435355 @default.
• W2679423891 hasConcept C121608353 @default.
• W2679423891 hasConcept C126322002 @default.
• W2679423891 hasConcept C143998085 @default.
• W2679423891 hasConcept C159654299 @default.
• W2679423891 hasConcept C197934379 @default.
• W2679423891 hasConcept C203014093 @default.
• W2679423891 hasConcept C2777701055 @default.
• W2679423891 hasConcept C2778375690 @default.
• W2679423891 hasConcept C2778650287 @default.
• W2679423891 hasConcept C2781433595 @default.
• W2679423891 hasConcept C71924100 @default.
• W2679423891 hasConcept C90924648 @default.
• W2679423891 hasConcept C98274493 @default.
• W2679423891 hasConceptScore W2679423891C121608353 @default.
• W2679423891 hasConceptScore W2679423891C126322002 @default.
• W2679423891 hasConceptScore W2679423891C143998085 @default.
• W2679423891 hasConceptScore W2679423891C159654299 @default.
• W2679423891 hasConceptScore W2679423891C197934379 @default.
• W2679423891 hasConceptScore W2679423891C203014093 @default.
• W2679423891 hasConceptScore W2679423891C2777701055 @default.
• W2679423891 hasConceptScore W2679423891C2778375690 @default.
• W2679423891 hasConceptScore W2679423891C2778650287 @default.
• W2679423891 hasConceptScore W2679423891C2781433595 @default.
• W2679423891 hasConceptScore W2679423891C71924100 @default.
• W2679423891 hasConceptScore W2679423891C90924648 @default.
• W2679423891 hasConceptScore W2679423891C98274493 @default.
• W2679423891 hasIssue "15_suppl" @default.
• W2679423891 hasLocation W26794238911 @default.
• W2679423891 hasOpenAccess W2679423891 @default.
• W2679423891 hasPrimaryLocation W26794238911 @default.
• W2679423891 hasRelatedWork W1974892500 @default.
• W2679423891 hasRelatedWork W1997286876 @default.
• W2679423891 hasRelatedWork W2062109360 @default.
• W2679423891 hasRelatedWork W2081521066 @default.
• W2679423891 hasRelatedWork W2104885590 @default.
• W2679423891 hasRelatedWork W2150213518 @default.
• W2679423891 hasRelatedWork W2616581328 @default.
• W2679423891 hasRelatedWork W2800311363 @default.
• W2679423891 hasRelatedWork W3119432592 @default.
• W2679423891 hasRelatedWork W4205989018 @default.
• W2679423891 hasVolume "33" @default.
• W2679423891 isParatext "false" @default.
• W2679423891 isRetracted "false" @default.
• W2679423891 magId "2679423891" @default.
• W2679423891 workType "article" @default.